Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7766372 | 1.00 | SOAT1 (0.41) | SOAT1ALDH1A1MAPTNPSR1APOBEC3A | |
| SCHEMBL7766360 | 1.00 | SOAT1 (0.41) | SOAT1ALDH1A1MAPTNPSR1APOBEC3A | |
| SCHEMBL2914885 | 0.86 | ALDH1A1 (0.46) | SOAT1ALDH1A1MAPTNPSR1APOBEC3A | |
| SCHEMBL8920172 | 0.83 | ALDH1A1 (0.45) | SOAT1ALDH1A1MAPTNPSR1APOBEC3A | |
| SCHEMBL4812377 | 0.83 | MAPT (0.39) | SOAT1ALDH1A1MAPTNPSR1APOBEC3A | |
| SCHEMBL4807770 | 0.83 | MAPT (0.39) | SOAT1ALDH1A1MAPTNPSR1APOBEC3A | |
| SCHEMBL18501522 | 0.83 | MAPT (0.39) | SOAT1ALDH1A1MAPTNPSR1APOBEC3A | |
| SCHEMBL9310089 | 0.83 | CES2 (0.42) | ALDH1A1MAPTNPSR1APOBEC3AAPOBEC3G | |
| SCHEMBL8920168 | 0.83 | ALDH1A1 (0.45) | SOAT1ALDH1A1MAPTNPSR1APOBEC3A | |
| SCHEMBL9310086 | 0.83 | CES2 (0.42) | ALDH1A1MAPTNPSR1APOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| EP-4214189-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL Business Ltd (GB) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022058733-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS PLC (GB) | 2022-03-24 | — | — | WO | disclosed |
| EP-0854875-B1 | NEW CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-06-13 | — | — | EP | disclosed |
| US-6159961-A | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-12 | — | — | US | disclosed |
| US-5958914-A | FOR THE TREATMENT OF BACTERIAL INFECTIOUS DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-28 | — | — | US | disclosed |
| EP-0854875-A1 | NEW CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997012890-A1 | NEW CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-10 | — | — | WO | disclosed |
| US-4729991-A | SUBSTITUTED BY HETEROCYCLIC THIOMETHYL GROUP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-03-08 | — | — | US | disclosed |
| US-4703046-A | Cephem compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | TTR, C1R, APOB | SOAT1 2050/4885ALDH1A1 1891/4885MAPT 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.